All In Biotech

NDA 019886 · Pfizer

Synarel

Nafarelin Acetate · Nasal

Novel

Last checked: Nov 20, 2026Latest source record: Nov 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1990

Feb 13, 1990

Approved uses

2

Original approval plus efficacy supplements

Registered trials

10

1 Phase 3, 3 recruiting

FAERS reports

273

225 serious, 9 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 5, 2026.

INDICATIONS AND USAGE FOR CENTRAL PRECOCIOUS PUBERTY (For Endometriosis, See Reverse Side ) SYNAREL is indicated for treatment of central precocious puberty (CPP) (gonadotropin-dependent precocious puberty) in children of both sexes. The diagnosis of central precocious puberty (CPP) is suspected when premature development of secondary sexual characteristics occurs at or before the age of 8 years in girls and 9 years in boys, and is accompanied by significant advancement of bone age and/or a poor adult height prediction. The diagnosis should be confirmed by pubertal gonadal sex steroid levels and a pubertal LH response to stimulation by native GnRH. Pelvic ultrasound assessment in girls usually reveals enlarged uterus and ovaries, the latter often with multiple cystic formations. Magnetic resonance imaging or CT-scanning of the brain is recommended to detect hypothalamic or pituitary tumors, or anatomical changes associated with increased intracranial pressure. Other causes of sexual precocity, such as congenital adrenal hyperplasia, testotoxicosis, testicular tumors and/or other autonomous feminizing or masculinizing disorders must be excluded by proper clinical hormonal and diagnostic imaging examinations. INDICATIONS AND USAGE FOR ENDOMETRIOSIS (For Central Precocious Puberty, See Reverse Side ) SYNAREL is indicated for management of endometriosis, including pain relief and reduction of endometriotic lesions. Experience with SYNAREL for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 24, 1998 Supplement 13 · Efficacy LetterReview
  • Feb 13, 1990 Original approval · Type 1 - New Molecular Entity
1 products under this application
  • SYNAREL · NAFARELIN ACETATE EQ 0.2MG BASE/SPRAY · SPRAY, METERED, NASAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Nafarelin" as an intervention, any sponsor and status, largest first.

All 10 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • ovarian hyperstimulation syndrome48
  • dyspnoea19
  • ascites18
  • condition aggravated13
  • diarrhoea13
  • headache13
  • nausea13
  • off label use13
  • pain13
  • abdominal pain12
  • drug ineffective11
  • malaise11

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044
20056
20063
20074
20085
20095
201034
201113
201212
201310
201421
201513
201615
201717
201814
201910
20208
202113
202216
202314
202416
202515
20265

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Synarel (Nafarelin Acetate)

2024 spending

$230K

Beneficiaries

15

71 claims

Per beneficiary

$15,316

$377.87 per unit

View as table
YearSpending
2020$364,740
2021$259,542
2022$211,702
2023$203,562
2024$229,747

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 85 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.